9 results about "Single isomer" patented technology

The present invention relates to a method for preparing a single isomer of 1-(1-(2-benzylphenoxy)propan-2-yl)-2-methylpiperidine in high purity.

The present invention relates to a method for preparing a high-purity 1-(1-(2-benzylphenoxy)propyl-2-yl)-2-methylpiperidine single isomer.

The present invention generally relates to the use of single isomer chemically modified cyclodextrins, i.e., S-(carboxyalkyl)-thio-cyclodextrin salts in medicaments for preventing or treating lysosomal storage diseases. More specifically, the present invention relates to isomerically pure, single isomer hexa-S-(carboxyalkyl)-hexathio-α-cyclodextrin sodium salt, heptath-S-(carboxyalkyl)-heptathio-β-cyclodextrin sodium salt, and octa-S-(carboxyalkyl)-octathio-γ-cyclodextrin sodium salt in medicaments for preventing or treating lysosomal storage diseases.

The invention relates to a separation and detection method of a ginsenoside Rh2 chiral isomer, and relates to the field of analytical chemistry. The separation and detection method of the ginsenoside Rh2 chiral isomer comprises two steps of test sample preparation and chromatographic separation condition setting, and normal phase HPLC chiral separation conditions are as follows: on a # imgabs0 # chromatographic column, the mobile phase is n-hexane-ethanol (v: v = 70: 30), the flow rate of the mobile phase is 1.0 mL min <-1 >, the column temperature is 25 DEG C, the sample size of a sample solution is 20 [mu] L, and the detection wavelength is 210 nm. Through setting of a specific chromatographic column and chromatographic conditions, separation and optical purity detection of the ginsenoside Rh2 chiral isomer can be realized, and a guarantee is provided for research and development of a single isomer ginsenoside Rh2.

The present invention relates to a novel pyrazine structure FXR agonist, a preparation method and application thereof, and specifically to a compound of the following general formula, a hydrate, a solvate, a pharmaceutically acceptable salt or a single isomer thereof, which has the effect of treating non-alcoholic fatty liver disease.

The present invention relates to a method for providing a single isomer chemical entity targeting vector suitable for providing a label of the targeting vector. The method applies a specific combination between dienes and dienophiles with complementary reverse electron demand Diels-Alder cycloaddition reactivity that will form a single isomer form of the compound after ligation and then oxidation. The labeled single isomer chemical entity targeting vectors are useful in therapy, radiotherapy, therapeutic diagnosis, diagnosis, and imaging. The methods employ click chemistry in which one chemical entity conjugated to the label is clicked together with a second chemical entity having complementary anti-electron demand Diels-Alder cycloaddition reactivity that is conjugated to a targeting carrier and then rapidly oxidized to form a single isomeride compound.

The present invention relates to a novel FXR agonist having a pyrazine structure, a preparation method therefor and the use thereof, and in particular relates to a compound as represented by the following general formula (I), or a hydrate, a solvate or a pharmaceutically acceptable salt thereof or a resolved single isomer thereof, which has the effect of treating non-alcoholic fatty liver disease.

The present invention generally relates to use of single isomer chemically modified cyclodextrins, namely, S-(carboxyalkyl)-thio-cyclodextrin salts in medication used for the prevention or treatment of lysosomal storage diseases.More particularly, the present invention relates to isomer-pure, single isomer hexakis-S-(carboxyalkyl)-hexathio-alpha-cyclodextrin sodium salts, heptakis-S-(carboxyalkyl)-heptathio-beta-cyclodextrin sodium salts and octakis-S-(carboxyalkyl)-octathio-gamma-cyclodextrin sodium salts in medication used for the prevention or treatment of lysosomal storage diseases.